Amyotrophic lateral sclerosis

New England Journal of Medicine

Volumn 344, Issue 22, 2001, Pages 1688-1700

  Rowland, Lewis P ^a,b   Shneider, Neil A ^a  

^a NEUROLOGICAL INSTITUTE   (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ANTIVIRUS AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BRANCHED CHAIN AMINO ACID; CALCIUM BINDING PROTEIN; COPPER; CREATINE; DEXTROMETHORPHAN; GABAPENTIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; LAMOTRIGINE; NEUROTROPHIC FACTOR; PERIPHERIN; PEROXYNITRITE; PROTEIN BCL 2; RILUZOLE; SELEGILINE; SELENIUM; SOMATOMEDIN; SUPEROXIDE DISMUTASE; UBIDECARENONE; UNINDEXED DRUG; XALIPRODEN; ZINC;

AMYOTROPHIC LATERAL SCLEROSIS; CALCIUM HOMEOSTASIS; CLINICAL EXAMINATION; COPPER METABOLISM; DEPRESSION; DISEASE CLASSIFICATION; DISEASE COURSE; ENZYME ACTIVITY; GENE MUTATION; GENETIC SUSCEPTIBILITY; HEREDITARY MOTOR SENSORY NEUROPATHY; HISTOPATHOLOGY; HUMAN; KENNEDY DISEASE; NEUROFILAMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SPINAL MUSCULAR ATROPHY; ZINC METABOLISM;

AMYOTROPHIC LATERAL SCLEROSIS; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOTOR NEURONS; MUTATION; SUICIDE, ASSISTED; SUPEROXIDE DISMUTASE;

EID: 0035978743     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200105313442207     Document Type: Review

References (148)

1. Rowland LP. Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1998;160:Suppl 1:S6-S24.
2. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. Arch Neurol 2000;57:1171-6.
3. Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988;24: 73-8.
4. Chaudhry V. Multifocal motor neuropathy. Semin Neurol 1998;18:73-81.
5. Van den Berg Vos RM, Fransscn H, Wokke JH, Van Es HW, Van den Berg LH. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann Neurol 2000;48:919-26.
6. Katz JS, Wolfe GI, Bryan WW, Jackson CE, Amato AA, Barohn RJ. Electrophysiologic findings in multifocal motor neuropathy. Neurology 1997;48:700-7.
7. Ellis CM, Leary S, Payan J, et al. Use of human intravenous immunoglobulin in lower motor neuron syndromes. J Neurol Neurosurg Psychiatry 1999;67:15-9.
8. Molinuevo JL, Cruz-Martinez A, Graus F, Serra J, Ribalta T, Valls-Sole J. Central motor conduction time in patients with multifocal motor conduction block. Muscle Nerve 1999;22:926-32.
9. Olney RK, Yuen EC, Engstrom JW. Statistical motor unit number estimation: reproducibility and sources of error in patients with amyotrophic lateral sclerosis. Muscle Nerve 2000;23:193-7.
10. Gooch C, Harati Y. Motor unit number estimation, ALS and clinical trials. ALS Other Mot Neuron Disord 2000;1:71-82.
11. Chan S, Shungu DC, Douglas-Akinwande A, Lange DJ, Rowland LP. Motor neuron diseases: comparison of single-voxel proton MR spectroscopy of the motor cortex with MR imaging of the brain. Radiology 1999; 212:763-9.
12. Pioro EP, Majors AW, Mitsumoto H, Nelson DR, Ng TC. 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Neurology 1999;53:71-9.
13. Triggs WJ, Menkes D, Onorato J, et al. Transcranial magnetic stimulation identifies upper motor neuron involvement in motor neuron disease. Neurology 1999;53:605-11.
14. Cole N, Siddique T. Genetic disorders of motor neurons. Semin Neurol 1999;19:407-18.
15. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62. [Erratum, Nature 1993;364:362.]
16. Andersen PM, Nilsson P, Keranen ML, et al. Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. Brain 1997;120:1723-37.
17. Al-Chalabi A, Andersen PM, Chioza B, et al. Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder: evidence for a linked protective factor. Hum Mol Genet 1998;7: 2045-50.
18. Cudkowicz ME, McKenna-Yasek D, Chen C, Hedley-Whyte ET, Brown RH. Limited corticospinal tract involvement in amyotrophic lateral sclerosis subjects with the A4V mutation in the copper/zinc superoxide dismutase gene. Ann Neurol 1998;43:703-10.
19. Rowland LP. Molecular basis of genetic heterogeneity: role of the clinical neurologist. J Child Neurol 1998;13:122-32.
20. Ben Hamida M, Hentati F, Ben Hamida C. Hereditary motor system diseases (chronic juvenile amyotrophic lateral sclerosis): conditions combining a bilateral pyramidal syndrome with limb and bulbar amyotrophy. Brain 1990;113:347-63.
21. Chance PF, Rabin BA, Ryan SG, et al. Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. Am J Hum Genet 1998;62:633-40.
22. Hosler BA, Siddique T, Sapp PC, et al. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA 2000;284:1664-9.
23. Hentati A, Bejaoui K, Pericak-Vance MA, et al. Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35. Nat Genet 1994;7:425-8.
24. Hentati A, Ouahchi K, Pericak-Vance MA, et al. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers. Neurogenetics 1998;2:55-60.
25. Majoor-Krakauer D, Ottman R, Johnson WG, Rowland LP. Familial aggregation of amyotrophic lateral sclerosis, dementia, and Parkinson's disease: evidence of shared genetic susceptibility. Neurology 1994;44:1872-7.
26. Cruz DC, Nelson LM, McGuire V, Longstreth WT. Physical trauma and family history of neurodegenerative diseases in amyotrophic lateral sclerosis: a population-based case-control study. Neuroepidemiology 1999; 18:101-10.
27. Brait K, Fahn S, Schwarz GA. Sporadic and familial parkinsonism and motor neuron disease. Neurology 1973;23:990-1002.
28. Qureshi AI, Wilmot G, Dihenia B, Schneider IA, Krendel DA. Motor neuron disease with parkinsonism. Arch Neurol 1996;53:987-91.
29. Lynch T, Sano M, Marder KS, et al. Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology 1994;44:1878-84.
30. Ceroni M, Malaspina A, Poloni TE, et al. Clustering of ALS patients in central Italy due to the occurrence of the L84F SOD1 gene mutation. Neurology 1999;53:1064-71.
31. Arnold A, Edgren DC, Palladino VS. Amyotrophic lateral sclerosis: fifty cases observed on Guam. J Nerv Ment Dis 1953;117:135-9.
32. McGeer PL, Schwab C, McGeer EG, Haddock RL, Steele JC. Familial nature and continuing morbidity of the amyotrophic lateral sclerosis-parkinsonism dementia complex of Guam. Neurology 1997;49:400-9.
33. Berger MM, Kopp N, Vital C, Redl B, Aymard M, Lina B. Detection and cellular localization of enterovirus RNA sequences in spinal cord of patients with ALS. Neurology 2000;54:20-5.
34. Walker MP, Schlaberg R, Hays AP, Bowser R, Lipkin WI. Absence of echovirus sequences in brain and spinal cord of amyotrophic lateral sclerosis patients. Ann Neurol 2001;49:249-53.
35. Swanson NR, Fox SA, Mastaglia FL. Search for persistent infection with poliovirus or other enteroviruses in amyotrophic lateral sclerosis-motor neurone disease. Neuromuscul Disord 1995;5:457-65.
36. Halperin JJ. Nervous system Lyme disease. J Neurol Sci 1998;153: 182-91.
37. Salazar AM, Masters CL, Gajdusek DC, Gibbs CJ. Syndromes of amyotrophic lateral sclerosis and dementia: relation to transmissible Creutzfeldt-Jakob disease. Ann Neurol 1983;14:17-26.
38. Worrall BB, Rowland LP, Chin SS, Mastrianni IA. Amyotrophy in prion diseases. Arch Neurol 2000;57:33-8.
39. Appel SH, Smith RG, Alexianu MF, Engelhardt JI, Stefani E. Autoimmunity as an etiological factor in sporadic amyotrophic lateral sclerosis. Adv Neurol 1995;68:47-57.
40. Appel S. ALS: immune factors in motor neuron cell injury. In: Neurobiology of ALS: education program syllabus. Minneapolis: American Academy of Neurology, 1999:101-13.
41. Pullen AH, Humphreys P. Ultrastructural analysis of spinal motoneurones from mice treated with IgG from ALS patients, healthy individuals, or disease controls. J Neurol Sci 2000;180:35-45.
42. Vincent A, Drachman DB. Amyotrophic lateral sclerosis and antibodies to voltage-gated calcium channels - new doubts. Ann Neurol 1996;40: 691-3.
43. Verma A, Berger JR, Snodgrass S, Petito C. Motor neuron disease: a paraneoplastic process associated with anti-hu antibody and small-cell lung carcinoma. Ann Neurol 1996;40:112-6.
44. Khwaja S, Sripathi N, Ahmad BK, Lennon VA. Paraneoplastic motor neuron disease with type 1 Purkinje cell antibodies. Muscle Nerve 1998; 21:943-5.
45. Hays AP, Roxas A, Sadiq SA, et al. A monoclonal IgA in a patient with amyotrophic lateral sclerosis reacts with neurofilaments and surface antigen on neuroblastoma cells. J Neuropathol Exp Neurol 1990;49:383-98.
46. Ferracci F, Fassetta G, Butler MH, Floyd S, Solimena M, De Camilli P. A novel antineuronal antibody in a motor neuron syndrome associated with breast cancer. Neurology 1999;53:852-5.
47. Gordon PH, Rowland LP, Younger DS, et al. Lymphoproliferative disorders and motor neuron disease: an update. Neurology 1997;48:1671-8.
48. Openshaw H, Slatkin NE. Motor neuron disease in Hodgkins lymphoma. Neurology 1998;50:Suppl 4:A31. abstract.
49. Case records of the Massachusetts General Hospital (Case 16-1999). N Engl J Med 1999;340:1661-9.
50. Kikuchi S, Ogata A, Shinpo K, et al. Detection of an Amadori product, 1-hexitol-lysine, in the anterior horn of the amyotrophic lateral sclerosis and spinobulbar muscular atrophy spinal cord: evidence for early involvement of glycation in motoneuron diseases. Acta Neuropathol (Berl) 2000;99:63-6.
51. Chou SM, Wang HS, Taniguchi A, Bucala R. Advanced glycation end-products in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis. Mol Med 1998;4:324-32.
52. Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol 1998;24:104-17.
53. Borthwick GM, Johnson MA, Ince PG, Shaw PJ, Turnbull DM. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann Neurol 1999;46: 787-90.
54. Beal M. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 2000;23:298-304.
55. Pons R, Andreetta F, Wang CH, et al. Mitochondrial myopathy simulating spinal muscular atrophy. Pediatr Neurol 1996;15:153-8.
56. Comi GP, Bordoni A, Salani S, et al. Cytochrome c oxidasc subunit I microdeletion in a patient with motor neuron disease. Ann Neurol 1998; 43:110-6.
57. Gonatas NK, Gonatas JO, Stieber A. The involvement of the Golgi apparatus in the pathogenesis of amyotrophic lateral sclerosis, Alzheimer's disease, and ricin intoxication. Histochem Cell Biol 1998;109:591-600.
58. Cleveland DW. From Charcot to SOD1: mechanisms of selective motor neuron death in ALS. Neuron 1999;24:515-20.
59. Wong PC, Rothstein JD, Price DL. The genetic and molecular mech anisms of motor neuron disease. Curr Opin Neurobiol 1998;8:791-9.
60. Deng HX, Hentati A, Tainer JA, et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 1993;261: 1047-51.
61. Bowling AC, Schulz JB, Brown RH, Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1993;61:2322-5.
62. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994;264:1772-5. [Erratum, Science 1995;269:149.]
63. Reaume AG, Elliott JL, Hoffman EK, et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 1996;13:43-7.
64. Beckman JS, Carson M, Smith CD, Koppenol WH. ALS, SOD and peroxynitrite. Nature 1993;364:584.
65. Beal MF, Ferrante RI, Browne SE, Matthews RT, Kowall NW, Brown RH. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 1997;42:644-54.
66. Ferrante RJ, Shinobu LA, Schulz JB, et al. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol 1997;42:326-34.
67. Estevez AG, Crow JP, Sampson JB, et al. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 1999;286:2498-500.
68. Crow JP, Sampson JB, Zhuang Y, Thompson JA, Beckman JS. Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. J Neurochem 1997;69:1936-44.
69. Corson LB, Strain JJ, Culotta VC, Cleveland DW. Chaperone-facilitated copper binding is a property common to several classes of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants. Proc Natl Acad Sci USA 1998;95:6361-6.
70. Wong PC, Waggoner D, Subramaniam JR, et al. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase. Proc Natl Acad Sci USA 2000;97:2886-91.
71. Durham HD, Roy J, Dong L, Figlewicz DA. Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J Neuropathol Exp Neurol 1997;56:523-30.
72. Cleveland DW, Liu J. Oxidation versus aggregation - how do SOD1 mutants cause ALS? Nat Med 2000;6:1320-1.
73. Carpenter S. Proximal axonal enlargement in motor neuron disease. Neurology 1968;18:841-51.
74. Hirano A, Donnenfeld H, Sasaki S, Nakano I. Fine structural observations of neurofilamentous changes in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 1984;43:461-70.
75. Rouleau GA, Clark AW, Rooke K, et al. SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis. Ann Neurol 1996;39:128-31.
76. Ince PG, Tomkins J, Slade JY, Thatcher NM, Shaw PJ. Amyotrophic lateral sclerosis associated with genetic abnormalities in the gene encoding Cu/Zn superoxide dismutase: molecular pathology of five new cases, and comparison with previous reports and 73 sporadic cases of ALS. J Neuropathol Exp Neurol 1998;57:895-904.
77. Julien JP, Beaulieu JM. Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects? J Neurol Sci 2000;180:7-14.
78. Eyer J, Cleveland DW, Wong PC, Peterson AC. Pathogenesis of two axonopathies does not require axonal neurofilaments. Nature 1998;391: 584-7.
79. Xu Z, Cork LC, Griffin JW, Cleveland DW. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell 1993;73:23-33.
80. Cote F, Collard JF, Julien JP. Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 1993;73:35-46.
81. Figlewicz DA, Krizus A, Martinoli MG, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 1994;3:1757-61.
82. Al-Chalabi A, Andersen PM, Nilsson P, et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 1999;8:157-64.
83. Mersiyanova IV, Perepelov AV, Polyakov AV, et al. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet 2000;67:37-46.
84. Willard M, Simon C. Modulations of neurofilament axonal transport during the development of rabbit retinal ganglion cells. Cell 1983;35:551-9.
85. Collard JF, Cote F, Julien JP. Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature 1995,375:61-4.
86. Williamson TL, Bruijn LI, Zhu Q, et al. Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis linked superoxide dismutase 1 mutant. Proc Natl Acad Sci USA 1998;95:9631-6.
87. Couillard-Despres S, Zhu Q, Wong PC, Price DL, Cleveland DW, Julien JP. Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase. Proc Natl Acad Sci USA 1998;95:9626-30.
88. Lefebvre S, Mushynski WE. Characterization of the cation-binding properties of porcine neurofilaments. Biochemistry 1988;27:8503-8.
89. Corbo M, Hays AP. Peripherin and neurofilament protein coexist in spinal spheroids of motor neuron disease. J Neuropathol Exp Neurol 1992; 51:531-7.
90. Tu PH, Raju P, Robinson KA, Gurney ME, Trojanowski JQ, Lee VM. Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci U S A 1996;93:3155-60.
91. Troy CM, Muma NA, Greene LA, Price DL, Shelanski ML. Regulation of peripherin and neurofilament expression in regenerating rat motor neurons. Brain Res 1990;529:232-8.
92. Troy CM, Brown K, Greene LA, Shelanski ML. Ontogeny of the neuronal intermediate filament protein, peripherin, in the mouse embryo. Neuroscience 1990;36:217-37.
93. Sterneck E, Kaplan DR, Johnson PF. Interleukin-6 induces expression of peripherin and cooperates with Trk receptor signaling to promote neuronal differentiation in PC12 cells. J Neurochem 1996;67:1365-74.
94. Beaulieu JM, Nguyen MD, Julien JP. Late onset death of motor neurons in mice overexpressing wild-type peripherin. J Cell Biol 1999;147: 531-44.
95. Bergeron C, Beric-Maskarel K, Muntasser S, Weyer L, Somerville MJ, Percy ME. Neurofilament light and polyadenylated mRNA levels are decreased in amyotrophic lateral sclerosis motor neurons. J Neuropathol Exp Neurol 1994;53:221-30.
96. Beaulieu JM, Robertson J, Julien JP. Interactions between peripherin and neurofilaments in cultured cells: disruption of peripherin assembly by the NF-M and NF-H subunits. Biochem Cell Biol 1999;77:41-5.
97. Siklos L, Engelhardt JI, Alexianu ME, Gurney ME, Siddique T, Appel SH. Intracellular calcium parallels motoneuron degeneration in SOD-1 mutant mice. J Neuropathol Exp Neurol 1998;57:571-87.
98. Elliott JL, Snider WD. Parvalbumin is a marker of ALS-resistant motor neurons. Neuroreport 1995;6:449-52.
99. Vanselow BK, Keller BU, Calcium dynamics and buffering in oculomotor neurones from mouse that are particularly resistant during amyotrophic lateral sclerosis (ALS)-related motoneurone disease. J Physiol 2000; 525:433-45.
100. Sommer B, Kohler M, Sprengel R, Seeburg PH. RNA editing in brain controls a determinant of ion flow in glutamate gated channels. Cell 1991;67:11-9.
101. Terro F, Yardin C, Esclaire F, Ayer-Lelievre C, Hugon J. Mild kainate toxicity produces selective motoneuron death with marked activation of CA(2+)-permeable AMPA/kainate receptors. Brain Res 1998;809:319-24.
102. Williams TL, Day NC, Ince PG, Kamboj RK, Shaw PJ. Calcium-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1997;42:200-7.
103. Takuma H, Kwak S, Yoshizawa T, Kanazawa I. Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol 1999;46:806-15.
104. Rothstein JD. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol 1995;68:7-20.
105. Shaw PJ, Ince PG. Glutamate, excitotoxicity and amyotrophic lateral sclerosis. J Neurol 1997;244:Suppl 2:S3-S14.
106. Rothstein JD, Tsai G, Kunrl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18-25.
107. Shaw PJ, Forrest V, Ince PG, Richardson JP, Wastell HJ. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995;4:209-16.
108. Rothstein JD, Dykes Hoherg M, Pardo CA, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996;16:675-86.
109. Rothstein JD. Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. Clin Neurosci 1995;3:348-59.
110. Lin CL, Bristol LA, Jin L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998;20:589-602.
111. Meyer T, Fromm A, Munch C, et al. The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals. J Neurol Sci 1999;170:45-50.
112. Nagai M, Abe K, Okamoto K, Itoyama Y. Identification of alternative splicing forms of GLT-1 mRNA in the spinal cord of amyotrophic lateral sclerosis patients. Neurosci Lett 1998;244:165-8.
113. Honig LS, Chambliss DD, Bigio EH, Carroll SL, Elliott JL. Glutamate transporter EAAT2 splice variants occur not only in ALS, but also in AD and controls. Neurology 2000;55:1082-8.
114. Trotti D, Rolfs A, Danbolt NC, Brown RH, Hediger MA. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci 1992;2:427-33. [Erratum, Nat Neurosci 1999;2:848.]
115. Carriedo SG, Sensi SL, Yin HZ, Weiss JH. AMPA exposures induce mitochondrial Ca(2+) overload and ROS generation in spinal motor neurons in vitro. J Neurosci 2000;20:240-50.
116. Carri MT, Fern A, Battistoni A, et al. Expression of a Cu,Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis induces mitochondrial alteration and increase of cytosolic Ca2+ concentration in transfected neuroblastoma SH-SY5Y cells. FEBS Lett 1997;414:365-8.
117. Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apopto sis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999;58:459-71.
118. He BP, Strong MJ. Motor neuronal death in sporadic amyotrophic lateral sclerosis (ALS) is not apoptotic: a comparative study of ALS and chronic aluminium chloride neurotoxicity in New Zealand white rabbits. Neuropathol Appl Neurobiol 2000;26:150-60.
119. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999;15:269-90.
120. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322-6.
121. Kostic V, Jackson-Lewis V, de Bilbao F, Dubois-Dauphin M, Przedborski S. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 1997;277:559-62.
122. Friedlander RM, Brown RH, Gagliardini V, Wang J, Yuan J. Inhibition of ICE slows ALS in mice. Nature 1997;388:31. [Erratum, Nature 1998;392:560.]
123. Li M, Ona VO, Guégan C, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000;288:335-9.
124. Bensimon G, Lacomblez L, Meininger V, ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-91.
125. Lacomblez L, Bensimon G, Leigh PN, et al. A confirmatory dose-ranging study of riluzole in ALS. Neurology 1996;47:Suppl 4:S242-S250.
126. Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 1998;55:526-8.
127. Miller RG. Clinical trials in motor neuron diseases. J Child Neurol 1999;14:173-9.
128. Demacrschalk BM, Strong MJ. Amyotrophic lateral sclerosis. Curr Treat Options Neurol 2000;2:13-22.
129. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-57.
130. Miller R, Gelinas D, Moore D, et al. A phase III placebo-controlled trial of gabapentin in amyotrophic lateral sclerosis. Ann Neurol 1999;46: 494. abstract.
131. Desnuelle C, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of ALS. ALS Other Mot Neuron Disord 2001;2:9-18.
132. Wechsler IS. Recovery in amyotrophic lateral sclerosis: treated with tocopherols (vitamin E): preliminary report. JAMA 1940;114:948-50.
133. Kaddurah Daouk R, Beal M. Amyotrophic lateral sclerosis: transgenic model and novel neuroprotective agent (creatine). Neurosci Res Commun 2000;26:215-26.
134. Mitsumoto H, Tsuzaka K. Neurotrophic factors and neuro-muscular disease. II. GDNF, other neurotrophic factors, and future directions. Muscle Nerve 1999;22:1000-21.
135. Drachman DB, Rothstein JD. Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. Ann Neurol 2000;48:792-5.
136. Hurko O, Walsh FS. Novel drug development for amyotrophic lateral sclerosis. J Neurol Sci 2000;180:21-8.
137. Ganzini L, Johnston WS, Hoffman WF. Correlates of suffering in amyotrophic lateral sclerosis. Neurology 1999;52:1434-40.
138. Rabkin JG, Wagner GJ, Del Bene M. Resilience and distress among amyotrophic lateral sclerosis patients and caregivers. Psychosom Med 2000; 62:271-9.
139. Simmons Z, Bremer BA, Robbins RA, Walsh SM, Fischer S. Quality of life in ALS depends on factors other than strength and physical function. Neurology 2000;55:388-92.
140. Murphy PL, Albert SM, Weber CM, Del Bene ML, Rowland LP. Impact of spirituality and religiousness on outcomes in patients with ALS. Neurology 2000;55:1581-4.
141. Miller RG, Rosenberg JA, Gelinas DF, et al. The care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999;52:1311-23.
142. O'Reilley D. The urgency of 'guerrilla science' as families push to find a cure now. San Francisco Examiner. March 14, 2000.
143. Weiner J. Curing the incurable. The New Yorker. February 7, 2000: 64-73.
144. Rowland LP. Six important themes in amyotrophic lateral sclerosis (ALS) research, 1999. J Neurol Sci 2000;180:2-6.
145. Idem. Assisted suicide and alternatives in amyotrophic lateral sclerosis. N Engl J Med 1998;339:987-9.
146. Albert SM, Murphy PL, Del Bene ML, Rowland LP. Prospective study of palliative care in ALS: choice, timing, outcomes. J Neurol Sci 1999;169:108-13.
147. Idem. A prospective study of preferences and actual treatment choices in ALS. Neurology 1999;53:278-83.
148. Ganzini L, Johnston WS, McFarland BH, Tolle SW, Lee MA. Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide. N Engl J Med 1998;339:967-73.